Supriya Saha, MD, PhD

Supriya Saha, MD, PhD

Assistant Member
Human Biology Division
Assistant Member
Clinical Research Division


Harvard University, Cambridge, 2001, BA (Biochemical Sciences)
David Geffen School of Medicine at UCLA, Los Angeles, 2008, MD, PhD
Brigham and Women’s Hospital, Boston, 2010, Residency in Internal Medicine
Dana-Farber/Harvard Cancer Center, 2014, Fellowship in Medical Oncology

Research Focus

The Saha Laboratory studies a highly lethal form of liver cancer called cholangiocarcinoma, or biliary tract cancer, which has been increasing in incidence worldwide for decades. We use a series of unique model systems that we have developed, including genetically engineered mouse models, patient-derived xenografts and cell lines to understand the fundamental pathogenic mechanisms of liver carcinogenesis and to identify new targeted therapies for specific genetic subsets of this disease. Our long-term goal is to transform the standard of care in cholangiocarcinoma from combination chemotherapy for all patients to ‘precision medicine’ with a specific targeted therapy regimen designed for each patient’s molecular profile.

Clinical Expertise

In addition to running a laboratory, Dr. Saha is a medical oncologist with a clinical interest in liver cancer, particularly cholangiocarcinoma and hepatocellular carcinoma.

Additional Links & Information

Related Labs & Projects

View all labs & projects >
Supriya Saha, MD, PhD

Contact Information

Additional contact

Mail Stop: C1-015